Pancreatic Cancer - Drug Pipeline Analysis and Market Forecasts to 2016

Pancreatic Cancer - Drug Pipeline Analysis and Market Forecasts to 2016

Summary

GlobalData's pharmaceutical and healthcare report offering, “Pancreatic Cancer – Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global pancreatic cancer market. This pharma report identifies the key trends shaping and driving the global pancreatic cancer market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global pancreatic cancer sector.

The pancreatic cancer market is forecast to exhibit a negative CAGR of 4.1% between 2009 and 2016. This drop in revenues is mainly due to the estimated patent expiry of Gemzar and also for Xeloda. Although the new products that are currently in Phase III will enter the market soon, it will take some time for physicians to shift their present pattern of usage from Gemzar to the new products. While the genericization of Gemzar will influence the market revenues, no substantial improvement in the unmet need is expected. Newer entrants might exhibit promising results but they have yet to prove their efficacy. Overall, the pancreatic cancer market, which showed a healthy growth between 2001 and 2009, is predicted to witness a decline in revenues between 2009 and 2014.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

Scope

The scope of the report includes:

• Annualized global pancreatic cancer revenues data from 2001 to 2009, forecast forward for 7 years to 2016.
• Geographic markets covered in this report include the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France, and Japan.
• Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends.
• Analysis of the current and future market competition in the global pancreatic cancer market. The key market players covered are Pfizer, Wilex Inc and NewLink Genetics.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for the future market associated with pancreatic cancer.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:

• Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global pancreatic cancer market.
• Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global pancreatic cancer market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global pancreatic cancer market landscape? – Identify, understand and capitalize.

1 Table of contents 

1.1 List of Tables 

1.2 List of Figures 

2 Pancreatic Cancer: Market Characterization 

2.1 Overview 

2.2 Pancreatic Cancer Market Size 

2.3 Pancreatic Cancer Market Forecast and CAGR 

2.4 Drivers and Barriers for the Pancreatic Cancer Market 

2.4.1 Drivers of the Pancreatic Cancer Market 

2.4.2 Barriers for the Pancreatic Cancer Market 

2.5 Opportunity and Unmet Need 

2.6 Key Takeaway 

3 Pancreatic Cancer Market: Competitive Assessment 

3.1 Overview 

3.2 Strategic Competitor Assessment 

3.3 Gemzar 

3.3.2 Gemcitabine Based Combinations 

3.3.3 Tarceva 

3.4 Key Takeaway 

4 Pancreatic Cancer: Pipeline Assessment 

4.1 Overview 

4.2 Strategic Pipeline Assessment 

4.2.1 Technology Trends Analytic Framework 

4.3 Pancreatic Cancer Therapeutics - Promising Drugs under Clinical Development 

4.4 Drugs under Clinical Development 

4.4.1 HyperAcute Pancreas 

4.4.2 Sutent 

4.4.3 Mesupron 

4.5 Pancreatic Cancer Therapeutics Market - Clinical Pipeline by Mechanism of Action 

4.6 Pancreatic Cancer Pipeline - Pipeline by Clinical Phase of Development 

4.6.1 Pancreatic Cancer Therapeutics - Phase III Clinical Pipeline 

4.6.2 Pancreatic Cancer Therapeutics - Phase II Clinical Pipeline 

4.6.3 Pancreatic Cancer Therapeutics - Phase I Clinical Pipeline 

4.6.4 Pancreatic Cancer Therapeutics - Preclinical Pipeline 

4.6.5 Pancreatic Cancer Therapeutics - Discovery Pipeline 

4.7 Discontinued / Suspended Drugs for Pancreatic Cancer 

4.8 Key Takeaway 

5 Pancreatic Cancer Market: Implications for Future Market Competition 

6 Pancreatic Cancer Market: Future Players in the Pancreatic Cancer Market 

6.1 Introduction 

6.2 Wilex Inc 

6.2.1 Overview 

6.2.2 Oncology Pipeline Portfolio 

6.2.3 Pancreatic Cancer Product Portfolio 

6.3 NewLink Genetics 

6.3.1 Overview 

6.3.2 Business Description 

6.3.3 Oncology Pipeline Portfolio 

6.3.4 Pancreatic Cancer Product Portfolio 

6.4 Pfizer 

6.4.1 Overview 

6.4.2 Business Description 

6.4.3 Oncology Pipeline Portfolio 

6.4.4 Pancreatic Cancer Product Portfolio 

7 Pancreatic Cancer Market: Appendix 

7.1 Market Definitions 

7.2 Acronyms 

7.3 Research Methodology 

7.3.1 Coverage 

7.3.2 Secondary Research 

7.3.3 Forecasting 

7.3.4 Primary Research 

7.3.5 Expert Panels 

7.4 Contact Us 

7.5 Disclaimer 

7.6 Sources